ENDOCUR - Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults

Overweight Clinical Trial

— ENDOCUR  

Official title:

Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03329781
• Other study ID #: 200130089
• Status: Completed
• Phase: N/A
• Start date: February 2015
• Est. completion date: January 2018

Study information

• Verified date: April 2021
• Source: University of Glasgow
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic diseases such as diabetes, cardiovascular diseases and cancer are a major burden on the Scottish population. Obesity and inflammation have strong links to these diseases. One of the mechanisms explaining the relationship between low-grade inflammation and excess weight is "endotoxaemia". We wish to study this phenomenon, when small components coming from our gut bacteria can pass into the bloodstream, raising the body's defences. Diet can modulate endotoxaemia. In this study, we propose to use curcumin, in a capsule form, to modulate endotoxaemia. Curcumin comes from turmeric, which is widely used as a spice. In this study, we want to test the effect of consuming curcumin extract to the composition of the gut microbiota, post-meal endotoxaemia, and inflammatory markers in blood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• BMI > 25 kg/m2.

Exclusion Criteria:

• having chronic inflammatory or autoimmune disease, gastrointestinal complaints or known biliary obstruction (past and present)

• use of anti-inflammatory drugs 2 weeks before the start of the study

• use of antibiotics during the 12 weeks preceding the trial

• pregnancy

• lactation

Related Conditions & MeSH terms

• Endotoxemia
• Overweight

Intervention

Dietary Supplement:
• BCM-95
Consuming 1 capsule of BCM-95 per day.
• Placebo
Consuming 1 placebo capsule per day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Glasgow

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of endotoxin in plasma.		21 days